How I treat cancer-associated thrombosis

Horsted, 2012, Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis, PLoS Med, 9, 10.1371/journal.pmed.1001275 Heit, 2015, Epidemiology of venous thromboembolism, Nat Rev Cardiol, 12, 464, 10.1038/nrcardio.2015.83 Cohoon, 2016, Direct medical costs attributable to cancer-associated venous thromboembolism: a population-based longitudinal study, Am J Med, 129, 10.1016/j.amjmed.2016.02.030 Merkow, 2014, Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer, Ann Surg, 260, 372, 10.1097/SLA.0000000000000378 Elting, 2004, Outcomes and cost of deep venous thrombosis among patients with cancer, Arch Intern Med, 164, 1653, 10.1001/archinte.164.15.1653 Khorana, 2007, Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy, J Thromb Haemost, 5, 632, 10.1111/j.1538-7836.2007.02374.x Chew, 2006, Incidence of venous thromboembolism and its effect on survival among patients with common cancers, Arch Intern Med, 166, 458, 10.1001/archinte.166.4.458 Sørensen, 2000, Prognosis of cancers associated with venous thromboembolism, N Engl J Med, 343, 1846, 10.1056/NEJM200012213432504 Hutten, 2000, Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis, J Clin Oncol, 18, 3078, 10.1200/JCO.2000.18.17.3078 Prandoni, 2002, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, 100, 3484, 10.1182/blood-2002-01-0108 Lee, 2003, Low-Molecular-Weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer, N Engl J Med, 349, 146, 10.1056/NEJMoa025313 Schulman, 2015, Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer, Thromb Haemost, 114, 150, 10.1160/TH14-11-0977 Prins, 2014, Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials, Lancet Haematol, 1, e37, 10.1016/S2352-3026(14)70018-3 Agnelli, 2015, Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the amplify trial, J Thromb Haemost, 13, 2187, 10.1111/jth.13153 Raskob, 2016, Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial, Lancet Haematol, 3, e379, 10.1016/S2352-3026(16)30057-6 van Es, 2014, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, 124, 1968, 10.1182/blood-2014-04-571232 Raskob, 2018, Edoxaban for the treatment of cancer-associated venous thromboembolism, N Engl J Med, 378, 615, 10.1056/NEJMoa1711948 Young, 2018, Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D), J Clin Oncol, 36, 2017, 10.1200/JCO.2018.78.8034 McBane, 2019, Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTe trial, J Thromb Haemost Agnelli, 2018, Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study, Thromb Haemost, 118, 1668, 10.1055/s-0038-1668523 Khorana, 2018, Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH, J Thromb Haemost, 16, 1891, 10.1111/jth.14219 Farge, 2019, 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol, 20, e566, 10.1016/S1470-2045(19)30336-5 Key, 2019, Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update, J Clin Oncol Samuelson Bannow, 2018, Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review, Res Pract Thromb Haemost, 2, 664, 10.1002/rth2.12111 Samuelson Bannow, 2018, Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH, J Thromb Haemost, 16, 1246, 10.1111/jth.14015 Gelosa, 2018, Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs), Pharmacol Res, 135, 60, 10.1016/j.phrs.2018.07.016 Short, 2014, New oral anticoagulants and the cancer patient, Oncologist, 19, 82, 10.1634/theoncologist.2013-0239 Riess, 2018, Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting, Oncologist, 23, 822, 10.1634/theoncologist.2017-0473 Hakeam, 2017, Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs), J Thromb Thrombolysis, 43, 343, 10.1007/s11239-016-1465-x Mani, 2013, Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations, J Thromb Thrombolysis, 36, 187, 10.1007/s11239-013-0907-y Byon, 2018, Regional gastrointestinal absorption of apixaban in healthy subjects, J Clin Pharmacol, 58, 965, 10.1002/jcph.1097 Parasrampuria, 2015, Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule, J Clin Pharmacol, 55, 1286, 10.1002/jcph.540 Martin, 2017, Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance, Am J Med, 130, 517, 10.1016/j.amjmed.2016.12.033 Marin-Romero, 2019, Extended treatment of cancer-associated thrombosis, Thromb Res, 181, 1, 10.1016/j.thromres.2019.07.003 Baumann Kreuziger, 2018, Wide variation in duration of anticoagulation after catheter-related thrombosis: a venous thromboembolism network US multicenter retrospective cohort study, Blood, 132, 10.1182/blood-2018-99-112206 Zwicker, 2014, Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: guidance from the SSC of the ISTH, J Thromb Haemost, 12, 796, 10.1111/jth.12527 Kopolovic, 2015, Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study, Ann Hematol, 94, 329, 10.1007/s00277-014-2198-6 Di Nisio, 2015, Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH, J Thromb Haemost, 13, 880, 10.1111/jth.12883 Wu, 2019, Update on management of portal vein thrombosis and the role of novel anticoagulants, J Clin Transl Hepatol, 7, 1, 10.14218/JCTH.2019.00008 Quencer, 2017, Tumor thrombus: incidence, imaging, prognosis and treatment, Cardiovasc Diagn Ther, 7, S165, 10.21037/cdt.2017.09.16 Kearon, 2016, Antithrombotic therapy for VTe disease: chest guideline and expert panel report, Chest, 149, 315, 10.1016/j.chest.2015.11.026 Ageno, 2016, Guidance for the management of venous thrombosis in unusual sites, J Thromb Thrombolysis, 41, 129, 10.1007/s11239-015-1308-1 Meyer, 2002, Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study, Arch Intern Med, 162, 1729, 10.1001/archinte.162.15.1729 Deitcher, 2006, Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period, Clin Appl Thromb Hemost, 12, 389, 10.1177/1076029606293692 Lee, 2015, Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial, JAMA, 314, 677, 10.1001/jama.2015.9243